Outcomes in COVID-19 brilacidin studies

0 0.5 1 1.5+ All studies 0% 1 120 Improvement, Studies, Patients Relative Risk Mortality 0% 1 120 RCTs 0% 1 120 Late 0% 1 120 Brilacidin for COVID-19 c19early.org December 2025 Favorsbrilacidin Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Innovati.. (DB RCT) 0% 1.00 [0.26-3.81] death 4/60 4/60 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 1. Late treatment 0% 1.00 [0.26-3.81] 4/60 4/60 no change All studies 0% 1.00 [0.26-3.81] 4/60 4/60 no change 1 brilacidin COVID-19 study c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 1. Effect extraction pre-specified(most serious outcome) Favors brilacidin Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Innovati.. (DB RCT) 0% 1.00 [0.26-3.81] 4/60 4/60 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 1. Late treatment 0% 1.00 [0.26-3.81] 4/60 4/60 no change All studies 0% 1.00 [0.26-3.81] 4/60 4/60 no change 1 brilacidin COVID-19 mortality result c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 1. Favors brilacidin Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Innovati.. (DB RCT) 0% 1.00 [0.26-3.81] death 4/60 4/60 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 1. Late treatment 0% 1.00 [0.26-3.81] 4/60 4/60 no change All studies 0% 1.00 [0.26-3.81] 4/60 4/60 no change 1 brilacidin COVID-19 serious outcome c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 1. Effect extraction pre-specified(most serious outcome) Favors brilacidin Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Innovati.. (DB RCT) -20% 1.20 [0.39-3.72] no recov. 6/60 5/60 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.76 Late treatment -20% 1.20 [0.39-3.72] 6/60 5/60 20% higher risk All studies -20% 1.20 [0.39-3.72] 6/60 5/60 20% higher risk 1 brilacidin COVID-19 recovery result c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.76 Favors brilacidin Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Innovati.. (DB RCT) 0% 1.00 [0.26-3.81] death 4/60 4/60 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 1. Late treatment 0% 1.00 [0.26-3.81] 4/60 4/60 no change All studies 0% 1.00 [0.26-3.81] 4/60 4/60 no change 1 brilacidin COVID-19 Randomized Controlled Trial c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 1. Effect extraction pre-specified(most serious outcome) Favors brilacidin Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Innovati.. (DB RCT) 0% 1.00 [0.26-3.81] 4/60 4/60 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 1. Late treatment 0% 1.00 [0.26-3.81] 4/60 4/60 no change All studies 0% 1.00 [0.26-3.81] 4/60 4/60 no change 1 brilacidin COVID-19 RCT mortality result c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 1. Favors brilacidin Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Innovati.. (DB RCT) 0% 1.00 [0.26-3.81] death 4/60 4/60 Improvement, RR [CI] Treatment Control Innovati.. (DB RCT) -33% 1.33 [0.31-5.70] death 4/60 3/60 Innovati.. (DB RCT) -33% 1.33 [0.31-5.70] death/int. 4/60 3/60 Innovati.. (DB RCT) -20% 1.20 [0.39-3.72] no recov. 6/60 5/60 Innovati.. (DB RCT) -8% 1.08 [0.84-1.39] recov. time 44 (n) 60 (n) Brilacidin COVID-19 outcomes c19early.org December 2025 Favors brilacidin Favors control